Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Bango 83.50p £60.43m (BGO.L) The mobile internet payment platform Company announces a trading update for the 12 months ended 31 December 2025, ahead of announcing FY25 Final Results in Q2.</li>
<li>The Company recorded positive cash EBITDA of approximately $2.3m, a $2.5m improvement from the negative Cash EBITDA of FY24.</li>
<li>The Company also expects the growth of Cash EBITDA to accelerate in FY26.</li>
</ul>


Bango 83.50p £60.43m (BGO.L) The mobile internet payment platform Company announces a trading update for the 12 months ended 31 December 2025, ahead of announcing FY25 Final Results in Q2.
The Company recorded positive cash EBITDA of approximately $2.3m, a $2.5m improvement from the negative Cash EBITDA of FY24.
The Company also expects the growth of Cash EBITDA to accelerate in FY26.


Hybridan Small Cap Feast: 20 January 2026

<ul>
<li>Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.</li>
<li>As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.</li>
<li>In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. </li>
</ul>


Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.
As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.
In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. 


Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

<ul>
<li>The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.</li>
<li>The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.</li>
<li>The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. </li>
</ul>


The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.
The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.
The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. 


Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

<p>On 4 November, Amur announced it had raised £1.2m (gross) via the issue of 70.6m shares at a price of 1.7p per share from an asset manager ‘specialising in natural resources’. This share issue is of material importance in advancing Amur towards completion of its mandatory Russian feasibility study (TEO) for its Kun-Manie nickel copper suphide project in Russia’s Far East. Due in December 2020, information included in the independently compiled TEO will also be incorporated in subsequent western feasibility study work.</p>

On 4 November, Amur announced it had raised £1.2m (gross) via the issue of 70.6m shares at a price of 1.7p per share from an asset manager ‘specialising in natural resources’. This share issue is of material importance in advancing Amur towards completion of its mandatory Russian feasibility study (TEO) for its Kun-Manie nickel copper suphide project in Russia’s Far East. Due in December 2020, information included in the independently compiled TEO will also be incorporated in subsequent western feasibility study work.

<p>Since producing its conceptual open-pit study in 2015, Amur has continued its exploration programme, as well as announcing the results of metallurgical tests on its ore by Russia’s premier metallurgical institute (Gipronickel), an open-pit/underground trade-off study and a review of costs (both undertaken by RPM). The results of these studies suggest a shift in likely mining to advance and increase underground operations. They have also allowed us to hone our assumptions to derive new valuations for each of Amur’s five potential development options.</p>

Since producing its conceptual open-pit study in 2015, Amur has continued its exploration programme, as well as announcing the results of metallurgical tests on its ore by Russia’s premier metallurgical institute (Gipronickel), an open-pit/underground trade-off study and a review of costs (both undertaken by RPM). The results of these studies suggest a shift in likely mining to advance and increase underground operations. They have also allowed us to hone our assumptions to derive new valuations for each of Amur’s five potential development options.

United Kingdom

Crism Therapeutics Corporation is a pharmaceutical manufacturing company. The Company specializes in improving the clinical implementation of active pharmaceutical ingredients (APIs) through local drug delivery and personalized medicines. Crism Therapeutics serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Crism Therapeutics (CRTX LN)

Hybridan Small Cap Feast: 20 January 2026

The mobile internet payment platform Company announces a trading update for the 12 months ended 31 December 2025, ahead of announcing FY25 Final...

Hybridan

Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at...

Hybridan

Hybridan Small Cap Feast: 27/03/2025

The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'.

Hybridan

Amur Minerals - Russian TEO status

On 4 November, Amur announced it had raised £1.2m (gross) via the issue of 70.6m shares at a price of 1.7p per share from an asset manager...

Edison Investment Research

Amur Minerals - Cobalt-plated nickel

Since producing its conceptual open-pit study in 2015, Amur has continued its exploration programme, as well as announcing the results of...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)